Search
Ramiprilat
go.drugbank.com/drugs/DB14208ExperimentalThe active metabolite of the prodrug Ramipril.
Categories: Agents Acting on the Renin-Angiotensin SystemZinlirvimab
go.drugbank.com/drugs/DB18867InvestigationalZinlirvimab is under investigation in clinical trial NCT03707977 (Dual Bnab Treatment in Children).
Synonyms: Anti-hiv-1 human monoclonal antibody targeting v3 glycan supersite on the hiv-1 envelope protein (10-1074)PF-06835919
go.drugbank.com/drugs/DB19163InvestigationalPF-06835919 is under investigation in clinical trial NCT05463575 (Ketohexokinase Inhibition in NAFLD).
Norethandrolone
go.drugbank.com/drugs/DB12787InvestigationalNorethandrolone is under investigation in clinical trial NCT00700544 (Treatment Outcome in Elderly Patients).
JNJ-28330835
go.drugbank.com/drugs/DB13936ExperimentalA selective androgen receptor modulator with minimal prostate hypertrophic activity, enhances lean body mass in male rats and stimulates sexual behavior in female rats.
GSK2798745
go.drugbank.com/drugs/DB16033InvestigationalGSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).
FF-10101-01
go.drugbank.com/drugs/DB16050InvestigationalFF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Darovasertib
go.drugbank.com/drugs/DB16059InvestigationalIDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).
Bemarituzumab
go.drugbank.com/drugs/DB16105InvestigationalBemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
Trastuzumab duocarmazine
go.drugbank.com/drugs/DB16342InvestigationalTrastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).